

amino acid sequences set forth in SEQ ID NO: 13, the sequence RTS, SEQ ID NO: 14, respectively; and  
 d) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 21, the sequence GAS, SEQ ID NO: 22, respectively.

**76.** The method of claim **74**, wherein the one or more antibodies comprises a variable heavy chain (VH) region and a variable light chain (VL) region comprising the amino acid sequences selected from the group consisting of:

- a) SEQ ID NO:4 and SEQ ID NO:7, respectively;
- b) SEQ ID NO:9 and SEQ ID NO:7, respectively;
- c) SEQ ID NO:12 and SEQ ID NO:15, respectively;
- d) SEQ ID NO:19 and SEQ ID NO:23, respectively;
- e) SEQ ID NO:20 and SEQ ID NO:23, respectively.

**77.** The method of claim **74**, wherein the Fc region of the one or more antibodies comprises the amino acid sequence selected from the group consisting of:

- a) SEQ ID NO:29;
- b) SEQ ID NO:30;
- c) SEQ ID NO:31;
- d) SEQ ID NO:32; and
- e) an amino acid sequence as defined in any one of a) to d) above having one to five mutations or substitutions in total across said sequence.

**78.** The method of claim **74**, wherein the one or more antibodies comprises a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences selected from the group consisting of:

- a) SEQ ID NO:33 and 39, respectively;
- b) SEQ ID NO:34 and 39, respectively;
- c) SEQ ID NO:35 and 39, respectively;
- d) SEQ ID NO:36 and 39, respectively;
- e) SEQ ID NO:37 and 39, respectively;
- f) SEQ ID NO:38 and 39, respectively;
- g) SEQ ID NO:40 and 43, respectively;
- b) SEQ ID NO:41 and 43, respectively; and
- c) SEQ ID NO:42 and 43, respectively.

**79.** A method of treating cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a carrier and one or more antibodies comprising a Fc region of a human immunoglobulin IgG and an antigen binding region binding to human DR5, wherein the Fc region comprises a mutation of an amino acid position corresponding to E430, E345 or S440 in human IgG1, wherein the numbering is according to the EU Index.

**80.** The method of claim **79**, wherein the one or more antibodies comprises a variable heavy chain (VH) region and a variable light chain (VL) region selected from the group consisting of:

- a) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 5, the sequence FAS, and SEQ ID NO: 6, respectively;
- b) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 1, 8, and 3,

respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 5, the sequence FAS, SEQ ID NO: 6, respectively;

- c) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 10, 2, and 11, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 13, the sequence RTS, SEQ ID NO: 14, respectively; and
- d) a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 21, the sequence GAS, SEQ ID NO: 22, respectively.

**81.** The method of claim **79**, wherein the one or more antibodies comprises a variable heavy chain (VH) region and a variable light chain (VL) region comprising the amino acid sequences selected from the group consisting of:

- a) SEQ ID NO:4 and SEQ ID NO:7, respectively;
- b) SEQ ID NO:9 and SEQ ID NO:7, respectively;
- c) SEQ ID NO:12 and SEQ ID NO:15, respectively;
- d) SEQ ID NO:19 and SEQ ID NO:23, respectively; and
- e) SEQ ID NO:20 and SEQ ID NO:23, respectively.

**82.** The method of claim **79**, wherein the Fc region of the one or more antibodies comprises the amino acid sequence selected from the group consisting of:

- a) SEQ ID NO:29;
- b) SEQ ID NO:30;
- c) SEQ ID NO:31;
- d) SEQ ID NO:32; and
- e) an amino acid sequence as defined in any one of a) to d) above having one to five mutations or substitutions in total across said sequence.

**83.** The method of claim **79**, wherein the one or more antibodies comprises a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences selected from the group consisting of:

- a) SEQ ID NO:33 and 39, respectively;
- b) SEQ ID NO:34 and 39, respectively;
- c) SEQ ID NO:35 and 39, respectively;
- d) SEQ ID NO:36 and 39, respectively;
- e) SEQ ID NO:37 and 39, respectively;
- f) SEQ ID NO:38 and 39, respectively;
- g) SEQ ID NO:40 and 43, respectively;
- b) SEQ ID NO:41 and 43, respectively; and
- c) SEQ ID NO:42 and 43, respectively.

**84.** The method of claim **79**, further comprising administering an additional therapeutic agent.

**85.** The method of claim **84**, wherein the additional therapeutic agent is one or more anti-cancer agents selected from the group consisting of: chemotherapeutics, kinase inhibitors, apoptosis-modulating agents, RAS inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nutraceuticals, cytokines, antibodies or antibody mimetics, and antibody-drug conjugates.

\* \* \* \* \*